Berkeley Lab researchers have developed technologies to evaluate levels of the long, non-coding RNA to assess the aggressiveness of a cancer and to modulate levels of the long non-coding RNA. This invention addresses the need to identify patients with potentially metastatic tumors versus non-metastatic tumors.
For more details, see Published PCT patent application 2015/031431.
STATUS: Issued U. S. Patent 10,364,470. Available for licensing or collaborative research.
REFERENCE NUMBER: 2014-109